CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Maloney Discusses Excitement With CAR T-Cell Therapy

October 18th 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Washington, discusses excitement with CAR T-cell therapy.

Dr. Wierda Discusses the Need for Newer Therapies in CLL

October 11th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for newer therapies in the treatment of chronic lymphocytic leukemia.

Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

October 11th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Maloney on Challenges With CAR T-Cell Therapy in ALL

October 10th 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of CAR T-cell therapy in acute lymphocytic leukemia.

CAR T Cells Highly Successful in ALL

October 9th 2017

Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.

Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy

September 20th 2017

Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

September 20th 2017

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

Expert Discusses Approval of First CAR T-Cell Therapy

September 18th 2017

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

FDA Puts Clinical Holds on "Off-the-Shelf" CAR-T Trials

September 6th 2017

The FDA placed clinical holds on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell (UCART) therapy known as UCART123.

Dr. Martin on Potential for CAR T-Cell Therapy in MCL Landscape

September 1st 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).

Novartis Sets a Price of $475,000 for CAR T-Cell Therapy

August 31st 2017

Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.

Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

August 30th 2017

Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.

FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy

August 30th 2017

The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

Gilead Acquires Kite Pharma in $11.9 Billion Deal

August 28th 2017

Gilead has announced plans to acquire Kite Pharma for $180.00 per share in cash, totaling approximately $11.9 billion.

Kumar Discusses Latest Developments in Myeloma

August 17th 2017

Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.

Speculation Mounts About Price Tag for Emerging CAR Therapies

August 17th 2017

Chimeric antigen receptor (CAR) T-cell therapies could spawn a new and lucrative industry in anticancer immunotherapy, resulting in single-infusion treatments costing hundreds of thousands of dollars, and even attracting medical tourism from abroad, where regulatory permissions are likely to come more slowly than in the United States.

CAR T Cells Show Promise in Relapsed/Refractory Hodgkin Lymphoma, ALCL

August 17th 2017

Researchers have determined that CD30-specific CAR T cells could be used safely and induce durable complete responses in patients with Hodgkin lymphoma and anaplastic large cell lymphoma.

Dr. Shah on Options for Ibrutinib-Intolerant Patients With MCL

August 11th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Dr. Roboz on Challenges With CAR T-cell Therapy in ALL

August 4th 2017

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Dr. Ansell on Combining CAR T-cell Therapy and Immunotherapy in Lymphomas

August 3rd 2017

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.